Picture loading failed.

Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-470-1mg 1mg 3090
GMP-Bios-ab-470-10mg 10mg 21890
GMP-Bios-ab-470-100mg 100mg 148000
GMP-Bios-ab-470-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-VEGFA therapeutic antibody (Pre-made Ranibizumab biosimilar,Fab)
INN Name Ranibizumab
TargetVEGFA
FormatFab
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure1cz8:HL:YX
99% SI StructureNone
95-98% SI Structure1bj1:HL:KJ/6bft:HL:AB
Year Proposed2004
Year Recommended2004
CompaniesGenentech;Manhattan Eye Ear & Throat Hospital;Novartis Ophthalmics;University of Bonn
Conditions ApprovedChoroidal neovascularisation;Degenerative myopia;Diabetic macular oedema;Retinal oedema;Wet age-related macular degeneration;Diabetic retinopathy
Conditions ActiveRetinopathy of prematurity;Polypoidal choroidal vasculopathy
Conditions DiscontinuedRetinal telangiectasis
Development Techna